Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases

Introduction Major depressive disorder (MDD) is a mental health disorder characterised by persistently low mood; anhedonia; feelings of worthlessness and guilt; altered appetite, weight and sleep and suicidal ideation. About one-third of patients do not respond to available antidepressants (AD). Tr...

Full description

Bibliographic Details
Main Authors:	A. Mercado-Rodríguez, C. Martín Requena, A. Cano Baena, I. Zorrilla Martínez, A. González-Pinto Arrillaga, L. Mar-Barrutia
Format:	Article
Language:	English
Published:	Cambridge University Press 2023-03-01
Series:	European Psychiatry
Online Access:	https://www.cambridge.org/core/product/identifier/S0924933823017455/type/journal_article

Similar Items

The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
by: D. Hernandez Huerta, et al.
Published: (2022-06-01)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
by: Maria Pepe, et al.
Published: (2023-10-01)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
by: Miriam Olivola, et al.
Published: (2022-02-01)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
by: Katrin Skala, et al.
Published: (2023-06-01)

Intranasal esketamine and the dawn of precision psychiatry
by: Devon Watts, et al.
Published: (2021-07-01)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
by: Enrico Capuzzi, et al.
Published: (2021-08-01)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
by: Maximilian Carter, et al.
Published: (2022-07-01)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
by: V. Martiadis, et al.
Published: (2022-06-01)

Intranasal Esketamine administration in catatonia: a case report.
by: J. Romay, et al.
Published: (2023-03-01)

Esketamine/ketamine for treatment-resistant depression
by: Acioly L.T. Lacerda
Published: (2020-05-01)

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
by: Gilmar Gutierrez, et al.
Published: (2022-05-01)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
by: V. Martiadis, et al.
Published: (2023-03-01)

Intranasal esketamine use in bipolar disorder: A case report
by: Courtney Skriptshak, PharmD, et al.
Published: (2021-07-01)

Comparing fast-acting interventions for treatment-resistant depression: An explorative study of accelerated HF-rTMS versus intranasal esketamine
by: Mauro Pettorruso, et al.
Published: (2023-07-01)

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01)

Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
by: Matteo Marcatili, et al.
Published: (2022-09-01)

How effective are ketamine or esketamine in treatment-resistant depression?
by: N. Veluri, et al.
Published: (2021-04-01)

Median effective dose of esketamine for intranasal premedication in children with congenital heart disease
by: Jiajia Huang, et al.
Published: (2023-04-01)

A randomized double-blind trial of intranasal dexmedetomidine versus intranasal esketamine for procedural sedation and analgesia in young children
by: Anna Nikula, et al.
Published: (2024-03-01)

Comparison of ketamine infusion, intranasal esketamine spray and repetitive Transcranial Magnetic Stimulation (rTMS) for treatment-resistant depression at a suburban tertiary clinic
by: Maria Cristina Davila, et al.
Published: (2022-09-01)

Esketamine following transcranial magnetic stimulation for treatment resistant depression
by: Aliaa Al-Sabbagh, et al.
Published: (2022-09-01)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
by: Johanna Louise Keeler, et al.
Published: (2023-05-01)

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
by: Maud Rothärmel, et al.
Published: (2022-07-01)

Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder
by: A. Safai Pour, et al.
Published: (2022-12-01)

Esketamine, a new treatment for resistant depression: a systematic review of the literature
by: Mercedes Valtueña García, et al.
Published: (2021-07-01)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
by: S. Faisant, et al.
Published: (2022-06-01)

Corrigendum to “Comparing fast-acting interventions for treatment-resistant depression: An explorative study of accelerated HF-rTMS versus intranasal esketamine” [Brain Stimul 16 (2023)]
by: Mauro Pettorruso, et al.
Published: (2023-09-01)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
by: J.K.E. Veraart, et al.
Published: (2023-05-01)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
by: E. Gaudre Wattinne, et al.
Published: (2021-04-01)

Clinical efficacy and tolerability of Esketamine: a case series
by: C. Passani, et al.
Published: (2022-06-01)

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study
by: Nagahide Takahashi, et al.
Published: (2021-10-01)

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression
by: Wajs, Ewa, et al.
Published: (2020)

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
by: Mohammed S Salahudeen, et al.
Published: (2020-07-01)

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
by: Kinza Degerlund Maldi, et al.
Published: (2021-12-01)

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
by: Sanne Y. Smith-Apeldoorn, et al.
Published: (2022-01-01)

Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
by: Peter Giacobbe, et al.
Published: (2022-09-01)

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
by: Lorena Catarina Del Sant, et al.
Published: (2022-12-01)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
by: Liu P, et al.
Published: (2022-12-01)

Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
by: Sanne Y. Smith-Apeldoorn, et al.
Published: (2020-01-01)